Biodesix, Inc. (NASDAQ:BDSX) Chairman John Patience Purchases 75,000 Shares

Biodesix, Inc. (NASDAQ:BDSX) Chairman John Patience bought 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were purchased at an average cost of $1.38 per share, for a total transaction of $103,500.00. Following the purchase, the chairman now owns 2,153,298 shares in the company, valued at $2,971,551.24. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Biodesix Price Performance

Shares of BDSX remained flat at $1.34 during mid-day trading on Wednesday. The stock had a trading volume of 797,321 shares, compared to its average volume of 159,360. Biodesix, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $2.21. The firm has a market capitalization of $194.54 million, a PE ratio of -3.40 and a beta of 1.22. The company has a current ratio of 3.28, a quick ratio of 3.28 and a debt-to-equity ratio of 0.99. The firm’s 50-day moving average price is $1.71 and its 200 day moving average price is $1.61.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings results on Friday, November 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $18.15 million for the quarter, compared to the consensus estimate of $18.45 million. Biodesix had a negative return on equity of 369.89% and a negative net margin of 66.84%. During the same quarter last year, the business posted ($0.12) EPS. As a group, sell-side analysts anticipate that Biodesix, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Scotiabank assumed coverage on Biodesix in a research report on Monday, September 16th. They issued a “sector outperform” rating and a $3.00 price target on the stock. Craig Hallum assumed coverage on Biodesix in a research report on Friday, July 26th. They issued a “buy” rating and a $3.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Biodesix presently has a consensus rating of “Buy” and an average price target of $3.06.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BDSX. AIGH Capital Management LLC lifted its position in Biodesix by 74.0% during the 2nd quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock worth $8,843,000 after acquiring an additional 2,458,727 shares during the period. Perceptive Advisors LLC acquired a new stake in Biodesix during the 2nd quarter worth approximately $3,326,000. Farallon Capital Management LLC acquired a new stake in Biodesix during the 2nd quarter worth approximately $2,874,000. Perkins Capital Management Inc. lifted its position in Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after acquiring an additional 310,000 shares during the period. Finally, CVI Holdings LLC acquired a new stake in Biodesix during the 2nd quarter worth approximately $59,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.